ProfileGDS5678 / 1445753_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 25% 25% 26% 23% 28% 25% 25% 27% 25% 26% 27% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6173125
GSM967853U87-EV human glioblastoma xenograft - Control 22.5826925
GSM967854U87-EV human glioblastoma xenograft - Control 32.5935326
GSM967855U87-EV human glioblastoma xenograft - Control 42.4813423
GSM967856U87-EV human glioblastoma xenograft - Control 52.5894928
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6479625
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6180125
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5959927
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5632425
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5923826
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6002527
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5946927
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6175827
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6110327